Evidence

Evidence tables

This table is a summary of the analysis reported in a Cochrane Clinical Answer that focuses on the above important clinical question.


Confidence in the evidence is high or moderate to high where GRADE has been performed and the intervention is more effective/beneficial than the comparison for key outcomes.


Population: Adults with hypotensive shock

Intervention: Noradrenaline ᵃ

Comparison: Dopamine ᵃ

OutcomeEffectiveness (BMJ rating)?Confidence in evidence (GRADE)?

All-cause mortality (at final follow-up, range unclear)

No statistically significant difference ᵇ

High

Duration of vasopressor treatment

Favours intervention

GRADE assessment not performed for this outcome

Duration of mechanical ventilation

No statistically significant difference

GRADE assessment not performed for this outcome

Arrhythmia

Favours intervention

High

Renal failure/renal replacement therapy

No statistically significant difference

GRADE assessment not performed for this outcome

Duration of Intensive Care Unit (ICU) stay

No statistically significant difference

GRADE assessment not performed for this outcome

Duration of hospital stay

No statistically significant difference

GRADE assessment not performed for this outcome

Quality of life

-

None of the studies identified by the review assessed this outcome

Note

ᵃ This evidence table summarises the findings for the comparison of noradrenaline versus dopamine, which is the main comparison as stated in the Cochrane review Summary of Findings table. See the full Cochrane Clinical Answer (CCA) for information on other comparisons (noradrenaline versus adrenaline [epinephrine]; noradrenaline versus terlipressin; noradrenaline versus vasopressin; noradrenaline versus phenylephrine; noradrenaline versus noradrenaline plus terlipressin plus dobutamine).

ᵇ All-cause mortality was 400/681 (58.7%) with noradrenaline compared with 454/719 (63.1%) with dopamine. However, this difference was not statistically significant. See the CCA for more details.

This evidence table is related to the following section/s:

Cochrane Clinical Answers

  • How does norepinephrine compare with other vasopressors in people with hypotensive shock?
    Show me the answer

Use of this content is subject to our disclaimer